Revenio Group Corporation: Revenio updates its financial guidance for 2020
December 17, 2020 at 10:30 am EST
Share
Revenio Group Corporation, Stock Exchange Release, December 17, 2020 at 17.30
Revenio updates its financial guidance for 2020
Revenio Group Corporation (“Revenio”, “Company”) refines its earnings guidance in terms of revenue mainly due to better-than-expected sales growth in the United States and estimates that the Company's net sales for July-December 2020 will be EUR 33.5–35.5 million and the growth to be very strong. Profitability excluding non-recurring costs is estimated to be at a strong level in accordance with the earnings guidance published on October 12, 2020.
Previous earnings guidance published on October 12, 2020: The Covid-19 pandemic continues to cause general uncertainty on the market and weakens visibility for the remainder of the year 2020. Under these circumstances Revenio Group Corporation estimates that the company's currency-adjusted net sales for July-December of the present year will grow strongly from the previous year and the profitability excluding non-recurring costs will be on a strong level.
Revenio Group Oyj, formerly Done Solutions Oyj, is a Finland-based company primarily engaged in the health technology segment. The Companyâs activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. It distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.
REVENIO GROUP OYJ 
